Introduction

Joint wear is common and can lead to pain, reduced movement and, over time, osteoarthritis. For people wanting a non-surgical option before considering more invasive treatments, understanding what is available — and what can realistically be expected — is an important starting point. This article looks at the safety record and suitability criteria for the ChondroFiller injection, a non-surgical, ultrasound-guided outpatient procedure.

Composition and How It Works

ChondroFiller is a Class III CE-marked medical device made by Meidrix Biomedicals in Germany. It is composed of purified Type I collagen and is supplied as a dual-component sterile syringe system. When the two components are mixed during injection, they form a self-gelling hydrogel scaffold in situ, typically within three to five minutes. The resulting acellular matrix settles within the joint and may provide a cushioning, protective layer over worn cartilage surfaces, helping to reduce grinding and mechanical irritation.

The device works on the principle of acellular matrix-induced chondrogenesis. Rather than introducing cells directly, the collagen scaffold acts as a chemotactic signal, attracting the patient's own progenitor cells from the surrounding synovium and subchondral bone marrow. Over time — typically one to two years — the scaffold is gradually resorbed and replaced by patient-derived, hyaline-like repair tissue. As it is cell-free, it is designed to avoid the biological complexity and cost associated with cell-based procedures.

Safety Record

ChondroFiller has been in clinical use since 2013. Across more than 19,000 units sold, no serious incidents have been reported to the manufacturer. The overall device complaint rate is very low, with non-gelation — the most common device-related issue — occurring in fewer than 0.01 per cent of cases. Clinical studies report a near-zero rate of procedure-related complications.

Because ChondroFiller is acellular and composed of highly purified collagen, the risk of allergic or immune reactions is very low. Longstanding clinical experience supports its biocompatibility across a range of joints, including the knee, hip, ankle and smaller joints of the hand. Most adverse effects reported in studies have been mild and related to the injection process itself rather than to the scaffold material.

Who May Benefit?

ChondroFiller as a non-surgical injection may be suitable for adults with osteoarthritis or localised focal joint wear who want to avoid an operation and whose lesion size and location are amenable to an injection approach. Smaller and more accessible lesions, or joints where the defect geometry does not require surgical preparation and precise scaffold placement under direct vision, tend to be the candidates most suited to the injection pathway.

People with very advanced arthritis affecting the whole joint surface, or where significant structural instability or large load-bearing defects are present, are generally less likely to be suitable for the injection alone. The appropriateness of the ChondroFiller injection is determined by clinical examination, relevant imaging, and a thorough discussion of realistic expectations. Benefits vary between individuals and cannot be guaranteed.

How It Compares with Other Options

Unlike microfracture surgery, which is an arthroscopic operation that stimulates the subchondral bone to produce a fibrocartilage repair, the ChondroFiller injection is a non-surgical, outpatient procedure with no incision, no general anaesthetic, and no theatre time. The collagen scaffold it delivers has the potential to support hyaline-like tissue regeneration, which is considered biomechanically superior to the fibrocartilage produced by microfracture.

For patients whose defect size, location or disease severity is beyond what an injection can practically address, a keyhole surgical approach may be more appropriate. The Liquid Cartilage procedure — Professor Paul Y. F. Lee's arthroscopic surgical protocol — delivers the ChondroFiller scaffold under direct vision, combined with biological adjuncts such as platelet-rich fibrin and, where indicated, the patient's own mesenchymal stem cells. That is a genuinely surgical pathway requiring theatre, anaesthetic, and a structured rehabilitation programme, and it is a different procedure from the non-surgical ChondroFiller injection. Which approach, if either, is suitable for any individual is a matter of clinical assessment rather than patient preference alone.

Conclusion

ChondroFiller is a non-surgical, cell-free collagen scaffold injection with a well-documented safety profile accumulated over more than a decade and tens of thousands of clinical uses. It is not a cure for arthritis and does not reverse structural joint changes. For people with localised joint wear who want a non-surgical first step, it may offer a meaningful option — but realistic expectations and individual suitability assessment are essential. For tailored advice, a consultation with a specialist in cartilage and joint preservation is the right starting point.

References

Corain M, Zanotti F, Giardini M, Gasperotti L, Invernizzi E, Biasi V, Lavagnolo U. The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage. 2023.